Statistics

Total Visits

Views
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r84

Select a period of time:

Number of views in the range

Views
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r28

Views

Views
November 20256
December 20250
January 20263
February 20260
March 20266
April 20260
May 202613
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States14
France3
Finland2
Germany2
Argentina1
Australia1
Colombia1
Ireland1
Italy1
Mexico1
 

Top cities views

Views
Aubervilliers3
Helsinki2
Blountsville2
Amsterdam1
Bastrop1
Brisbane1
Dublin1
Elgin1
Henderson1
Kalamazoo1